Alternative splicing for tuneable expression of protein subunits at desired ratios

References

• Dorai H, Csirke B, Scallon B, Ganguly S. Correlation of heavy and light chain mRNA copy numbers to antibody productivity in mouse myeloma production cell lines. Hybridoma (Larchmt). 2006;25(1):1–14. doi:10.1089/hyb.2006.25.1. PMID: 16475875.
   PubMedGoogle Scholar
• Schlatter S, Stansfield SH, Dinnis DM, Racher AJ, Birch JR, James DC. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Progress. 2005;21(1):122–33. doi:10.1021/bp049780w.
   PubMed Web of Science ®Google Scholar
• Ho SCL, Koh EYC, van Beers M, Mueller M, Wan C, Teo G, Song Z, Tong YW, Bardor M, Yang Y. Control of IgG LC: HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability. J Biotechnol. 2013;165(3–4):157–66. doi:10.1016/j.jbiotec.2013.03.019.
   PubMed Web of Science ®Google Scholar
• Blanco N, Williams AJ, Tang D, Zhan D, Misaghi S, Kelley RF, Simmons LC. Tailoring translational strength using Kozak sequence variants improves bispecific antibody assembly and reduces product-related impurities in CHO cells. Biotechnol Bioeng. 2020;117:1946–60. doi:10.1002/bit.27347. PMID: 32246763.
   PubMed Web of Science ®Google Scholar
• Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D’Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH. et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. Mabs-austin. 2013;5(5):646–54. doi:10.4161/mabs.25632. PMID: 23924797.
   PubMed Web of Science ®Google Scholar
• Rajendra Y, Peery RB, Hougland MD, Barnard GC, Wu X, Fitchett JR, Bacica M, Demarest SJ. Transient and stable CHO expression, purification and characterization of novel hetero-dimeric bispecific IgG antibodies. Biotechnol Prog. 2017;33:469–77. doi:10.1002/btpr.2414. PMID: 27977915.
   PubMed Web of Science ®Google Scholar
• Matasci M, Baldi L, Hacker DL, Wurm FM. The PiggyBac transposon enhances the frequency of CHO stable cell line generation and yields recombinant lines with superior productivity and stability. Biotechnol Bioeng. 2011;108:2141–50. doi:10.1002/bit.23167. PMID: 21495018.
   PubMed Web of Science ®Google Scholar
• Chng J, Wang T, Nian R, Lau A, Hoi KM, Ho SC, Gagnon P, Bi X, Yang Y. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. Mabs-austin. 2015;7(2):403–12. doi:10.1080/19420862.2015.1008351.
   PubMed Web of Science ®Google Scholar
• Ho SCL, Bardor M, Feng H, Tong YW, Song Z, Yap MGS, Yang Y. IRES-mediated Tricistronic vectors for enhancing generation of high monoclonal antibody expressing CHO cell lines. J Biotechnol. 2012;157(1):130–39. doi:10.1016/j.jbiotec.2011.09.023.
   PubMed Web of Science ®Google Scholar
• Cooper TA, Ordahl CP. A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing. J Biol Chem. 1985;260(20):11140–48. doi:10.1016/S0021-9258(17)39158-5. PMID: 2993302.
   PubMed Web of Science ®Google Scholar
• Dominski Z, Kole R. Selection of splice sites in pre-mRnas with short internal exons. Mol Cell biol. 1991;11(12):6075–83. doi:10.1128/MCB.11.12.6075. PMID: 1944277.
   PubMed Web of Science ®Google Scholar
• Ladd AN, Charlet N, Cooper TA. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol Cell biol. 2001;21:1285–96. doi:10.1128/MCB.21.4.1285-1296.2001. PMID: 11158314.
   PubMed Web of Science ®Google Scholar
• Ho TH, Charlet BN, Poulos MG, Singh G, Swanson MS, Cooper TA. Muscleblind proteins regulate alternative splicing. Embo J. 2004;23(15):3103–12. doi:10.1038/sj.emboj.7600300. PMID: 15257297.
   PubMed Web of Science ®Google Scholar
• Cooper TA. In vitro splicing of cardiac troponin T precursors. Exon mutations disrupt splicing of the upstream intron. J Biol Chem. 1992;267(8):5330–38. doi:10.1016/S0021-9258(18)42770-6. https://www.ncbi.nlm.nih.gov/pubmed/1544914 PMID: 1544914.
   PubMed Web of Science ®Google Scholar
• Cooper TA, Ordahl CP. Nucleotide substitutions within the cardiac troponin T alternative exon disrupt pre-mRNA alternative splicing. Nucleic Acids Res. 1989;17(19):7905–21. doi:10.1093/nar/17.19.7905.
   PubMed Web of Science ®Google Scholar
• Cooper TA, Cardone MH, Ordahl CP. Cis requirements for alternative splicing of the cardiac troponin T pre–mRNA. Nucl Acids Res. 1988;16(17):8443–65. https://www.ncbi.nlm.nih.gov/pubmed/3419923. PMID: 3419923.
   PubMed Web of Science ®Google Scholar
• Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005;37(4):331–40. doi:10.1016/j.ymeth.2005.07.015. PMID: 16314262.
   PubMed Web of Science ®Google Scholar
• Dominski Z, Kole R. Cooperation of pre-mRNA sequence elements in splice site selection. Mol Cell biol. 1992;12(5):2108–14. doi:10.1128/MCB.12.5.2108. PMID: 1569943.
   PubMed Web of Science ®Google Scholar
• Aebischer-Gumy C, Moretti P, Ollier R, Ries Fecourt C, Rousseau F, Bertschinger M. SPLICELECT™: an adaptable cell surface display technology based on alternative splicing allowing the qualitative and quantitative prediction of secreted product at a single-cell level. Mabs-austin. 2020;12(1):1709333. doi:10.1080/19420862.2019.1709333.
   PubMed Web of Science ®Google Scholar
• Lucas BK, Giere LM, DeMarco RA, Shen A, Chisholm V, Crowley CW. High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. Nucleic Acids Res. 1996;24:1774–79. https://www.ncbi.nlm.nih.gov/pubmed/8649999. PMID: 8649999.
   PubMed Web of Science ®Google Scholar
• Fallot S, Ben Naya R, Hieblot C, Mondon P, Lacazette E, Bouayadi K, Kharrat A, Touriol C, Prats H. Alternative-splicing-based bicistronic vectors for ratio-controlled protein expression and application to recombinant antibody production. Nucleic Acids Res. 2009;37(20):e134. doi:10.1093/nar/gkp716. PMID: 19729510.
   PubMed Web of Science ®Google Scholar
• Prentice inventor. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing.
   Google Scholar
• Aebischer-Gumy C, Bertschinger M, Moretti P (Inventors). Glenmark pharmaceuticals SA/Ichnos sciences SA s assignee.^assignees. Expression constructs and methods for expressing polypeptides in eukaryotic cells. WO2015018832.
   Google Scholar
• Gorman CM, Gies DR, McCray G. Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng Tech. 1990;2:1–28.
   Google Scholar
• Bell MV, Cowper AE, Lefranc MP, Bell JI, Screaton GR. Influence of intron length on alternative splicing of CD44. Mol Cell biol. 1998;18(10):5930–41. doi:10.1128/MCB.18.10.5930. PMID: 9742110.
   PubMed Web of Science ®Google Scholar
• Feige MJ, Buchner J. Principles and engineering of antibody folding and assembly. Biochim Biophys Acta. 2014;1844(11):2024–31. doi:10.1016/j.bbapap.2014.06.004. PMID: 24931831.
   PubMed Web of Science ®Google Scholar
• Spooner J, Keen J, Nayyar K, Birkett N, Bond N, Bannister D, Tigue N, Higazi D, Kemp B, Vaughan T. et al. Evaluation of strategies to control Fab light chain dimer during mammalian expression and purification: A universal one-step process for purification of correctly assembled Fab. Biotechnol Bioeng. 2015;112(7):1472–77. doi:10.1002/bit.25550. PMID: 25619171.
   PubMed Web of Science ®Google Scholar
• Read A, Schroder M. The unfolded protein response: an overview. Biology (Basel). 2021;10(5):384. doi:10.3390/biology10050384. PMID: 33946669.
   PubMedGoogle Scholar
• Running Deer J, Allison DS. High-level expression of proteins in Mammalian Cells using transcription regulatory sequences from the Chinese Hamster EF-1α Gene. Biotechnol Prog. 2004;20(3):880–89. doi:10.1021/bp034383r. PMID: 15176895.
   PubMed Web of Science ®Google Scholar
• Peltret M, Vetsch P, Farvaque E, Mette R, Tsachaki M, Frank J, Vaxeliare E, Moritz B, Aillerie C, Giovannini R. et al. Development of a 10 g/l process for a difficult-to-express multispecific antibody format using a holistic process development approach. Submitted To J Biotechnol. 2023.
   Google Scholar
• Tsubaki M, Terashima I, Kamata K, Koga A. C-terminal modification of monoclonal antibody drugs: amidated species as a general product-related substance. Int J Biol Macromol. 2013;52:139–47. doi:10.1016/j.ijbiomac.2012.09.016. PMID: 23022270.
   PubMed Web of Science ®Google Scholar
• Beck A, Liu H. Macro- and micro-heterogeneity of natural and recombinant IgG antibodies. Antibodies (Basel). 2019;8(1):18. doi:10.3390/antib8010018. PMID: 31544824.
   PubMedGoogle Scholar
• Biswas R, Belouski E, Graham K, Hortter M, Mock M, Tinberg CE, Russell AJ. VERITAS: Harnessing the power of nomenclature in biologic discovery. Mabs-austin. 2023;15(1):2207232. doi:10.1080/19420862.2023.2207232. PMID: 37162235.
   PubMed Web of Science ®Google Scholar
• Skegro D, Stutz C, Ollier R, Svensson E, Wassmann P, Bourquin F, Monney T, Gn S, Blein S. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J Biol Chem. 2017;292(23):9745–59. doi:10.1074/jbc.M117.782433. PMID: 28450393.
   PubMed Web of Science ®Google Scholar
• Xu R, Teng J, Cooper TA. The cardiac troponin T alternative exon contains a novel purine-rich positive splicing element. Mol Cell biol. 1993;13(6):3660–74. doi:10.1128/MCB.13.6.3660. PMID: 8388541.
   PubMed Web of Science ®Google Scholar
• Guo C, Chen F, Xiao Q, Catterall HB, Robinson JH, Wang Z, Mock M, Hubert R. Expression liabilities in a four-chain bispecific molecule. Biotechnol Bioeng. 2021;118(10):3744–59. doi:10.1002/bit.27850. PMID: 34110008.
   PubMed Web of Science ®Google Scholar
• Magistrelli G, Poitevin Y, Schlosser F, Pontini G, Malinge P, Josserand S, Corbier M, Fischer N. Optimizing assembly and production of native bispecific antibodies by codon de-optimization. Mabs-austin. 2017;9(2):231–39. doi:10.1080/19420862.2016.1267088. PMID: 28001485.
   PubMed Web of Science ®Google Scholar
• Lam N, Finney R, Yang S, Choi S, Wu X, Cutmore L, Andrade J, Huang L, Amatya C, Cam M. et al. Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions. Mol Ther Oncolytics. 2023;30:132–49. doi:10.1016/j.omto.2023.07.001. PMID: 37654973.
   PubMed Web of Science ®Google Scholar
• Rasmussen SK, Naested H, Muller C, Tolstrup AB, Frandsen TP. Recombinant antibody mixtures: production strategies and cost considerations. Arch Biochem Biophys. 2012;526(2):139–45. doi:10.1016/j.abb.2012.07.001. PMID: 22820097.
   PubMed Web of Science ®Google Scholar